Sensorion SA
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin def…
Biotechnology
FR, Montpellier [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q2 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 64.25 | 6.91 | 4.21 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 5649.93 | 6.26 | -0.11 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q2 | Δ in % | |
|---|---|---|---|---|
| Book Value | 77.37 | 0.32 | 0.18 | |
| Cash | 210.86 | 0.61 | 0.20 | |
| Capex | -38.76 | < 0.005 | < 0.005 | |
| Free Cash Flow | 21.69 | -0.05 | -0.06 | |
| Revenue | -26.40 | 0.01 | 0.02 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q2 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -2.68 | 0.82 | 0.84 | |
| Operating Margin | -99.13 | 0.04 | -4.36 | |
| ROA | 34.91 | -0.14 | -0.21 | |
| ROE | 43.35 | -0.17 | -0.29 | |
| ROIC | -99.53 | < 0.005 | -0.30 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of ALSEN.PA is permitted for members.
5
Growth
The "Growth Entry" for the Focus of ALSEN.PA is permitted for members.
6
Leverage & Liquidity